» Articles » PMID: 15017592

Loss of P53 Transcriptional Activity in Hepatocellular Carcinoma Evaluated by Yeast-based Functional Assay: Comparison with P53 Immunohistochemistry

Overview
Journal Hum Pathol
Specialty Pathology
Date 2004 Mar 16
PMID 15017592
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

We studied the transcriptional activity of p53 protein in 50 tissues of hepatocellular carcinoma (HCC) using a yeast functional assay. In this assay, red yeast colonies indicate that p53 protein cannot bind to its specific domain and has lost its transcriptional activity. We also clarified whether mutant p53 protein could inactivate wild-type p53 protein in a transdominant manner using a modified yeast assay. In addition, we examined whether immunohistochemically detectable p53 protein was functionally inactive. The incidence of p53 inactivation was significantly higher in tumors with capsular invasion. Out of 21 tumors diagnosed with p53 mutations, 11 exhibited >75% red colonies, and all contained missense mutations. In these tumors, p53 function was lost because there was supposedly no intact p53 gene on either allele. One missense mutant produced <60% red colonies, but it was also considered inactive as a p53 protein heterotetramer because of its transdominant activity. In 7 of the remaining 9 tumors, p53 was considered to be mutated on one allele and intact on the other. All of these 7 tumors contained nonsense or frameshift mutations and had no transdominant activity, which suggested that p53 function remained intact. Alternately, immunohistochemical analysis demonstrated that all of the tumors with missense mutations were positively immunostained, whereas those that contained nonsense or frameshift mutations were negatively stained. Consequently, positively immunostaining tumors mostly coincided with p53-inactive tumors. These yeast-based assays suggested that p53 function was retained in some mutant cases. Immunohistochemistry was helpful in screening functionally inactive p53 protein in HCCs.

Citing Articles

p53, p63 and p73 in the wonderland of .

Billant O, Blondel M, Voisset C Oncotarget. 2017; 8(34):57855-57869.

PMID: 28915717 PMC: 5593689. DOI: 10.18632/oncotarget.18506.


Nutlin-3a selects for cells harbouring TP53 mutations.

Kucab J, Hollstein M, Arlt V, Phillips D Int J Cancer. 2016; 140(4):877-887.

PMID: 27813088 PMC: 5215675. DOI: 10.1002/ijc.30504.


Immunohistochemical Determination of p53 Protein Overexpression for Predicting p53 Gene Mutations in Hepatocellular Carcinoma: A Meta-Analysis.

Liu J, Li W, Deng M, Liu D, Ma Q, Feng X PLoS One. 2016; 11(7):e0159636.

PMID: 27428001 PMC: 4948819. DOI: 10.1371/journal.pone.0159636.


Effects of temozolomide (TMZ) on the expression and interaction of heat shock proteins (HSPs) and DNA repair proteins in human malignant glioma cells.

Castro G, Cayado-Gutierrez N, Zoppino F, Fanelli M, Cuello-Carrion F, Sottile M Cell Stress Chaperones. 2014; 20(2):253-65.

PMID: 25155585 PMC: 4326375. DOI: 10.1007/s12192-014-0537-0.


Assessment of the Proliferative Marker Ki-67 and p53 Protein Expression in HBV- and HCV-related Hepatocellular Carcinoma Cases in Egypt.

Mohamed W, Omar M, Khayri T, Fakhr I Int J Health Sci (Qassim). 2011; 2(1):27-34.

PMID: 21475468 PMC: 3068722.